Generic Glivec market heating up

Published: 2013-06-04 06:57:00

Updated: 2013-06-04 06:57:00

Various generic forms of Glivec will flood the domestic market as Swiss pharmaceutical company Novartis’s patent rights to use a chemical substance essential to treat chronic myeloid leukemia expired on June 3.

According to the Ministry of Food and Drug Safety, a total of 31 generics produced ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK